Global Health Progress Launched to Drive Cross-sectoral Collaborations in Support of the Sustainable Development Goals (SDGs)
25.10.2019 02:00:00 EEST | Business Wire | Press release
To support the SDGs, with a particular focus on SDG 17: Partnership for The Goals, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has launched Global Health Progress. The knowledge hub highlights industry contributions to the SDGs and enhances opportunities for further collaboration.
2020 marks the 10-year countdown to the SDG deadline. Countries have made progress towards achieving the goals; however, complex health and wellbeing challenges remain – from poverty and inequality to climate change. Further, many countries are now faced with a double burden of disease – as they continue to tackle infectious disease challenges, they also battle with an increasing prevalence of non-communicable diseases (NCDs) – which present new issues in implementing effective and sustainable solutions for health.
Global Health Progress highlights over 200 collaborations which use innovative approaches to tackle global health challenges. The collaborations are helping to bring different actors together – governments, academia, multilateral organizations, other private sector companies, local NGOs and more – to catalyze cross-sector initiatives to tackle health related challenges, as well as address gender equality and education issues. A range of program strategies are being used to address systemic health issues and lay foundations to sustain program gains. In consultation with local actors, IFPMA member companies are fostering local ownership of programs and designing programs according to country’s specific health needs and existing health system infrastructure.
The collaborations are transforming traditional approaches to partnerships. For more information, visit Global Health Progress at www.globalhealthprogress.org
About IFPMA
IFPMA represents innovative biopharmaceutical companies and associations across the globe. The biopharmaceutical industry’s two million employees discover, develop, and deliver medicines and vaccines that improve the lives of patients worldwide. Based in Geneva, IFPMA has official relations with the UN and contributes industry expertise to help the global health community find solutions that improve health for populations around the world.
For more information, visit IFPMA at www.ifpma.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005021/en/
Contact information
Unjela Kaleem, Director of Communications
u.kaleem@ifpma.org
+41223383200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier28.5.2026 14:00:00 EEST | Press release
Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted. Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment. The Amadeus Travel Advertising Platform connects forward-looking travel demand intelligence with advertising planning, activation and AI-supported decision-making. This enables travel brands to drive profitable demand and decisions by investi
Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration28.5.2026 14:00:00 EEST | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry. This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and Veolia,will join Kinaxis executives to share how they are navigating disruption and improving operational outcomes. Kinaxis CEO, Razat Gaurav is set
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 13:28:00 EEST | Press release
Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling the initiation of rigorous clinical trials in the United Stat
LMR by IFF Inaugurates New Experimental Field in Grasse28.5.2026 12:00:00 EEST | Press release
LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—today inaugurated its new experimental field, Domaine des Naturels LMR. The field is dedicated to advancing research in natural ingredients, preserving Grasse’s agricultural heritage and expanding education in naturals. The inauguration, attended by Grasse Mayor Jérôme Viaud, a long-standing supporter of the perfume industry, underscores IFF and LMR’s ongoing commitment to the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527694524/en/ At Domaine des Naturels LMR, R&D experts research new natural species, variety breeding, cultivation methods and production techniques. “This inauguration reflects over two decades of continuous investment in Grasse and in naturals,” said Ana Paula Mendonça, president, Scent, IFF. “With Domaine des Naturels LMR, we are bringing together innovation, preservation and knowledge sharing to s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom